This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
Cabometyx
INN: cabozantinib
Data updated: 2026-05-02
Available in:
🇨🇿🇩🇪🇬🇧🇫🇷🇵🇹🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Ipsen Pharma
ATC Code
L01EX07
Source
EMA · EMEA/H/C/004163
(
ARTG
)
Renal Cell Carcinoma (RCC),CABOMETYX is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):
- in treatment-naïve adults with intermediate or poor risk
- in adults following prior treatment with vascular endothelial growth factor targeted therapy.
CABOMETYX in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,Hepatocellular Carcinoma (HCC),CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.,Differentiated Thyroid Carcinoma (DTC),CABOMETYX is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed during or after prior VEGFR-targeted therapy and who are radioactive iodine (RAI) refractory or ineligible.,Neuroendocrine Tumours (NET),CABOMETYX is indicated for the treatment of adult patients with locally advanced/unresectable or metastatic, well-differentiated extra-pancreatic (epNET) or pancreatic (pNET) neuroendocrine tumours who have progressed on at least one prior systemic therapy other than a somatostatin analogue.
⚠️ Warnings
• Caution should be exercised in patients with history of high blood pressure, coughing up blood or bleeding, open wound, liver problems, any allergy, who are taking other medications, during pregnancy and breastfeeding.
• Patient may develop severe bleeding episodes (serious effects) that can lead to death. If it is so consult with your healthcare provider.
• Stop this medication immediately if you have experienced any one of the following: fistula formation, severe hemorrhage, heart attack, stroke, nephrotic syndrome, osteonecrosis of the jaw and leukoencephalopathy syndrome.
